Coherus Oncology (NASDAQ:CHRS) Releases Earnings Results, Beats Estimates By $0.01 EPS

Coherus Oncology (NASDAQ:CHRS) released its quarterly earnings data on Monday. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01, FiscalAI reports. The company had revenue of $12.31 million for the quarter, compared to the consensus estimate of $14.22 million. Coherus Oncology had a negative return on equity of 192.84% and a net margin of 397.30%.

Here are the key takeaways from Coherus Oncology’s conference call:

• LOQTORZI net sales rose 61% year-over-year to $11.8M in Q1, new patient starts hit an all-time high, and management expects 10%–15% average quarterly demand growth in 2026 despite a weather-driven seasonal Q1 dip.
• The randomized CATALYST-202 HCC study (72 patients) has completed target accrual, with initial data and planned biomarker reads (IL-27 and circulating tumor DNA) expected around mid-year to assess contribution and earlier signals of efficacy.
• The tagmokitug CCR8 program is actively enrolling multiple cohorts (head & neck, upper GI, ESCC, MSS CRC) and launching a J&J pasritamig prostate cohort under a multi-cohort protocol, but the CCR8 field shows mixed results so clinical outcomes remain uncertain.
• Management emphasizes that tagmokitug meets their “right drug” pharmacology criteria (linear PK, potency, dose-dependent target effects and acceptable safety), which they cite as a differentiator versus some paused CCR8 programs.
• Coherus strengthened liquidity with a $54M net follow-on equity raise and ended Q1 with $167M in cash and investments, which management says is sufficient to fund key 2026–2027 data readouts and near-term development priorities.

Coherus Oncology Price Performance

CHRS stock opened at $1.71 on Wednesday. The firm has a market cap of $263.72 million, a P/E ratio of 1.02 and a beta of 1.01. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.45 and a current ratio of 1.47. Coherus Oncology has a 1 year low of $0.71 and a 1 year high of $2.62. The stock has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $1.63.

Coherus Oncology News Summary

Here are the key news stories impacting Coherus Oncology this week:

• Positive Sentiment: Guggenheim initiated coverage on Coherus Oncology with a Buy rating and a $12 price target, implying significant upside from recent trading levels. Guggenheim initiates coverage of Coherus Oncology (CHRS) with buy recommendation
• Neutral Sentiment: The company reported first-quarter 2026 financial results and provided a business update, which is likely keeping attention on the stock while investors assess execution and pipeline progress. Coherus Oncology, Inc.: Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Management’s earnings call transcript may provide additional detail on the company’s outlook, but by itself is not a direct catalyst. Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Q1 results came in below expectations, with EPS of -$0.27 versus estimates of -$0.26 and revenue of $12.31 million versus expectations of $14.22 million, reinforcing concerns about near-term financial performance. Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on CHRS shares. Wall Street Zen raised shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, March 14th. Oppenheimer initiated coverage on shares of Coherus Oncology in a research note on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price objective for the company. Guggenheim started coverage on shares of Coherus Oncology in a research report on Monday. They issued a “buy” rating and a $12.00 price objective for the company. Finally, Weiss Ratings raised shares of Coherus Oncology from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, April 22nd. Three research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Coherus Oncology has an average rating of “Moderate Buy” and an average price target of $8.67.

Institutional Investors Weigh In On Coherus Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new position in Coherus Oncology in the 3rd quarter worth $26,000. Blair William & Co. IL acquired a new stake in shares of Coherus Oncology during the fourth quarter valued at about $27,000. BNP Paribas Financial Markets increased its position in shares of Coherus Oncology by 108.2% during the third quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 13,832 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Coherus Oncology during the third quarter worth about $59,000. Finally, Focus Partners Wealth acquired a new position in shares of Coherus Oncology in the third quarter worth about $70,000. Hedge funds and other institutional investors own 72.82% of the company’s stock.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.